ALLOGENE THERAPEUTICS INC. - COMMON STOCK

2.4600

14-November-24 16:45:00

15 minutes delayed

Stocks

-0.2600

-9.56%

Today's range

2.4600 - 2.7527

ISIN

N/A

Source

NASDAQ

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

02 Aug 2023 16:02:00 By Nasdaq GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

26 Jul 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

15 Jun 2023 09:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Departure of Chief Financial Officer

14 Jun 2023 08:00:01 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

09 Jun 2023 18:25:18 By Nasdaq GlobeNewswire
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2023 09:00:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

24 May 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 May 2023 11:50:32 By Nasdaq GlobeNewswire
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

03 May 2023 16:02:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

26 Apr 2023 10:06:38 By Nasdaq GlobeNewswire
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

25 Apr 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

20 Apr 2023 16:05:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

17 Apr 2023 10:15:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

13 Apr 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

30 Mar 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

14 Mar 2023 17:30:48 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

02 Mar 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy

01 Mar 2023 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 16:02:00 By Nasdaq GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

21 Feb 2023 08:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.